Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
67.725
0.655 (0.98%)
Market Cap: 12.91 Bil
Enterprise Value: 12.43 Bil
PE Ratio: 40.55
PB Ratio: 2.38
GF Score: 69/100 
Biomarin Pharmaceutical Inc at SVB Leerink Global Healthcare (Virtual) Transcript
Feb 18, 2022 / 06:00PM GMT
Release Date Price:
$84.86
(-6.02%)
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - Senior MD of Rare Diseases & Senior Research Analyst
Everyone, welcome to this fireside chat with BioMarin Pharmaceuticals. I'm Joe Schwartz at SVB Securities. It's my pleasure to be joined by Hank Fuchs, President of Worldwide R&D. How are you doing, Hank?
Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development
Good to see you, Joe. Nice to be here.
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - Senior MD of Rare Diseases & Senior Research Analyst
So maybe we can start by having you give us a quick overview of the key [initiatives] the company has for this year and the major catalysts that investors should look forward to for your stock.
Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development
Great. Thanks, Joe. It's a pleasure to be here today to talk to you. 2022 is going to be our most productive
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers